Syneos Health

Overview

Syneos Health is an integrated biopharmaceutical solutions organization combining contract research (CRO) and contract commercial (CCO) capabilities under one operating roof, formed by the 2017 merger of INC Research and inVentiv Health. Buyers searching INC Research or inVentiv Health should evaluate Syneos Health as the active entity. In September 2023, Syneos was taken private at $7.1B EV by a PE consortium (Elliott Investment Management, Patient Square Capital, and Veritas Capital) operating as “Star Parent”; the company has run as a privately held PE-backed business since then, with no public financial disclosures.

Syneos is most relevant when clinical development, evidence strategy, field deployment, managed markets, and commercial execution need to connect across the same operating partner rather than move through separate CRO and CCO vendors. It is not a hub services platform, a specialty pharmacy, or a focused niche CRO; small protocols, narrow therapy-area programs, or buyers who want a single senior team’s attention may prefer a specialist alternative.

Clinical Trial Capability Model

The framework below standardizes how Rx Almanac evaluates clinical-trial-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Syneos Health is evaluated as integrated biopharmaceutical solutions organization combining contract research (CRO) and contract commercial (CCO) capabilities under one operating roof, formed by the 2017 merger of INC Research and inVentiv Health.

Capability	Buyer should compare	Syneos Health readout
Site selection and feasibility	Therapy-area site relationships, country mix, site activation timelines, and feasibility analytics.	Core site-selection work. Global CRO footprint with strong CNS and oncology heritage from INC Research roots; Q1 2026 Bestudy acquisition added Chinese CRO capacity.
Patient recruitment and retention	Referral workflows, screening, patient support during study conduct, and dropout reduction.	Recruitment work. Recruitment is part of the integrated CRO scope; ask for therapy-specific recruitment and dropout benchmarks.
Data management and biostatistics	EDC, data quality, statistical programming, biostatistics, and clinical data standards.	Trial data work. Standard global CRO scope; ask which platforms (e.g., WCG ClinSphere Trial IntelX) are deployed for the specific program.
Clinical operations and monitoring	Monitoring model, FSP, hybrid sourcing, GCP controls, and risk-based monitoring.	Core clinical operations. FSP 360 supports flexible functional service provider sourcing, useful for biotech sponsors that want hybrid CRO models.
Real-world evidence and HEOR	Late-phase studies, RWE generation, HEOR, payer evidence packages, and value dossiers.	Evidence work. Spherico market access brand covers HEOR, pricing and reimbursement, and payer strategy alongside the CRO and CCO units.
Regulatory and submission support	Regulatory strategy, agency interactions, submission planning, and global filing support.	Regulatory support. Regulatory and submission capabilities sit alongside the CRO; confirm therapy-specific regulatory references in the SOW.
Trial-to-commercial continuity	Continuity planning for patients, access transition, hub handoff, and early commercial operations.	Core trial-to-commercial handoff. The integrated CRO + CCO model is the headline differentiator for sponsors wanting one vendor across clinical and commercial; verify that handoff playbooks have been used on therapy analogs.

Buyer Fit

• Where it fits: Mid-to-large biopharma sponsors that want one operating partner across global CRO execution and US commercial deployment, particularly for launches where trial-to-commercial continuity, field deployment, and access need to move in sync.
• Best-fit buyers: Oncology, rare disease, immunology, neurology, cardiology, and cell and gene therapy sponsors needing global trial operations plus commercial execution; biotech sponsors using FSP 360 for hybrid sourcing.
• Less ideal fit: Small studies, niche therapy-area programs, or sponsors that want senior-team attention from a specialist CRO; PE-private status also reduces the public disclosure layer some diligence teams expect.
• Commercial fit: Custom/RFP scoping; PE-private status means there are no public quarterly disclosures, so diligence on operational stability, leadership tenure, and program references is more important than for public peers.
• Scope diligence: Therapy-area site relationships, named delivery leads, FSP versus full-service mix, biostat and data management platform, Spherico market access scope, trial-to-commercial handoff playbooks, and PE governance impact on long-term continuity.

Differentiators

• Integrated CRO + CCO under one operating roof: The 2017 INC Research / inVentiv Health merger created a vendor that spans clinical development and commercial execution; useful for launches needing trial-to-commercial continuity.
• Kinetic commercial analytics platform: AI-powered commercial analytics layer that connects to the CCO scope; ask for specific use cases that have moved to production.
• FSP 360 flexible sourcing: Functional service provider model that gives biotech sponsors a hybrid path between full outsourcing and full insourcing.
• Spherico market access brand: HEOR, pricing and reimbursement, and payer strategy capabilities that connect commercial execution to evidence and access work.
• Rare Disease Consortium: Orphan drug development capabilities and consortium model for rare-disease sponsors needing concentrated therapy-area expertise.

RFP Questions

• Which therapy-area sites, countries, and recruitment networks are already active for the specific protocol?
• Which team members are the named delivery leads across CRO, CCO, RWE, and market access, and what turnover protections apply?
• How does the FSP 360 model interact with the sponsor’s existing clinical operations team, and what governance applies?
• Which trial-to-commercial handoff playbooks have been used on therapy analogs, and what evidence supports the continuity claim?
• How does Spherico market access scope coordinate with the CRO and CCO units inside one operating cadence?
• What change-order, pass-through, and scope-discipline governance applies under the PE-private operating model?
• Which references can demonstrate clinical and commercial outcomes inside the same program?

Recent Activity

• 2026-05: Expanded causaLens partnership with agentic AI digital workers (multi-agentic causal-reasoning systems) for HCP targeting, sales territory design, and digital media campaigns.
• 2026-04: KAI Conversations partnership: AI-powered conversation intelligence platform for US pharma sales teams (real-time field rep coaching).
• 2026-03: Acquired Bestudy, a Chinese CRO, expanding clinical trial capabilities in China and the broader APAC region.
• 2026-02: Published survey on biopharma capital and dealmaking trends.
• 2024-10: Costa Panagos appointed CEO; Colin Shannon transitioned to Executive Chairman.
• 2023-09: Taken private at $7.1B EV ($43.00/share) by Elliott Investment Management, Patient Square Capital, and Veritas Capital consortium under the “Star Parent” PE umbrella.